Country for PR: Japan
Contributor: Kyodo News JBN
Tuesday, July 05 2022 - 17:00
EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement
FUKUOKA, Japan, July 5, 2022 /Kyodo JBN-AsiaNet/ --

EditForce, Inc. (Headquarters: Fukuoka, President and CEO: Takashi Ono; 
hereinafter "EditForce") has entered into a License Agreement (hereinafter 
"Agreement") with Mitsubishi Tanabe Pharma Corporation (Headquarters: Osaka, 
Representative Director: Hiroaki Ueno; hereinafter "MTPC") to research, develop 
and commercialize potential gene therapy products for a specific target disease 
in the field of CNS by utilizing EditForce's proprietary PPR protein platform 

Logo of EditForce, Inc.: 

In this alliance, MTPC and EditForce aim to create potential novel 
pharmaceuticals for the specific CNS disease by utilizing the drug R&D know-how 
and global business experience of MTPC and the novel biotechnology of 
EditForce. MTPC will acquire the exclusive right to conduct the selection of 
drug candidate molecules, preclinical and clinical development, manufacturing, 
and commercialization worldwide.

Under the terms of the Agreement, EditForce will receive an upfront payment and 
milestone payments amounting to over 20 billion yen depending on the 
development stage and commercialization progress, and royalties based on 
worldwide sales after the launch.

"I am so delighted to reach the agreement with MTPC, which has an interest in 
our proprietary PPR protein platform technology," said Takashi Ono, President 
and CEO of EditForce. "We look forward to working closely with MTPC to develop 
and deliver breakthrough pharmaceutical products with our technology to 
patients suffering from diseases."

EditForce will proceed with R&D of pharmaceuticals using its PPR protein 
platform technology.

About EditForce, Inc.
EditForce, Inc., a Kyushu University-originated venture company developing a 
unique DNA/RNA editing technology (PPR platform technology (*)), was 
established in May 2015 by KISCO Ltd. and Prof. Takahiro Nakamura of Kyushu 
University (former president of EditForce and currently its scientific advisor) 
and funded by companies and funds that have track records of investing in life 
sciences and biotechnology. EditForce aims for drug discovery that applies the 
PPR technology through joint research with universities and private companies. 

For more information, please visit

(*) Pentatricopeptide repeat (PPR) protein platform technology
PPR is a protein discovered in plants that regulates gene expression by binding 
to DNA and RNA in a sequence-specific manner. The PPR proteins are also found 
in humans and yeasts, and they have similar functions. Prof. Takahiro Nakamura 
and Dr. Yusuke Yagi, CTO of EditForce, have focused on the PPR proteins and 
elucidated the mechanism that determines sequence specificity, and established 
a technology for creating various PPR proteins, each of which binds to a 
specific target DNA or RNA sequence. Furthermore, it is possible to manipulate 
and modify the target genome and RNA both inside and outside the cell by fusion 
with effector proteins.

About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi 
Chemical Group (MCG), is one of the oldest pharmaceutical companies in the 
world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is 
headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical 
industry. MCG has positioned health care as its strategic focus in its 
management policy, "Forging the future." MTPC sets the MISSION of "Creating 
hope for all facing illness." To that end, MTPC is prioritizing work on 
"precision medicine" to provide drugs with high treatment satisfaction by 
identifying patient populations with high potential for efficacy and safety, 
focusing on the disease areas of the central nervous system and 
immuno-inflammation. In addition, MTPC is working to develop "around the pill 
solutions" to address specific patient concerns based on therapeutic medicine, 
including prevention of diseases, pre-symptomatic disease care, prevention of 
aggravation and prognosis. 

For more information, go to

Source: EditForce, Inc.